Condition Directory

Non-Small Cell Lung Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Non-Small Cell Lung Cancer. Browse Non-Small Cell Lung Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 7, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3700

Shown on this page

Current sort

How Non-Small Cell Lung Cancer studies are organized in the registry

NSCLC is one of the most biomarker-organized portfolios in the registry: EGFR, ALK, ROS1, KRAS G12C, and PD-L1 status define many study populations and appear verbatim in titles. Stage language also matters — stage III (often around chemoradiation) and stage IV/metastatic studies are designed differently and labeled accordingly.

Terms that often appear in related listings

EGFR ALK KRAS G12C stage III PD-L1

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 625–636 of 3,700 matching trials for Non-Small Cell Lung Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Savolitinib, Osimertinib, Pemetrexed, Cisplatin, Carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Orlando, Florida • Honolulu, Hawaii • New Brunswick, New Jersey + 2 more

Conditions: Non Small Cell Lung Cancer, Lung Cancer
Interventions: Osimertinib, Carotuximab; Drug
Lead sponsor: Karen Reckamp, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 5
States / cities: Beverly Hills, California • Los Angeles, California • Torrance, California

Conditions: Early Stage Non-small Cell Lung Cancer, Non-small Cell Lung Cancer
Interventions: Computed tomography-guided stereotactic adaptive radiotherapy, ETHOS; Radiation · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR Wt NSCLC, Platinum Resistant Ovarian Cancer, PROC
Interventions: HWK-007; Drug
Lead sponsor: Whitehawk Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 12
States / cities: Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 9 more

Conditions: Stage II Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer, NSCLC
Interventions: PERCC; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions: GEN1042, Pembrolizumab, Cisplatin, Carboplatin, 5-FU, Gemcitabine, Nab paclitaxel, Pemetrexed, Paclitaxel; Biological · Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 23
States / cities: Anchorage, Alaska • Los Alamitos, California • San Diego, California + 19 more

Conditions: Non Small Cell Lung Cancer (Stage III)
Interventions: Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 5
States / cities: Duarte, California • Atlanta, Georgia • Florham Park, New Jersey + 2 more

Conditions: Stage II-IIIB Non-small Cell Lung Carcinoma
Interventions: Osimertinib 80 mg/40 mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Santa Rosa, California • Las Vegas, Nevada • White Plains, New York

Conditions: Non-small Cell Lung Cancer
Interventions: Exercise; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab, Docetaxel; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Irvine, California • Los Alamitos, California • Orange, California + 3 more

Conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, NSCLC
Interventions: Radiation Therapy, Paclitaxel, Carboplatin, Ascorbic Acid; Drug
Lead sponsor: Joseph J. Cullen, MD, FACS; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions: Durvalumab, Radiation Therapy, Tremelimumab; Biological · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 41
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 29 more

About this Non-Small Cell Lung Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Non-Small Cell Lung Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Non-Small Cell Lung Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Non-Small Cell Lung Cancer clinical trials

How Non-Small Cell Lung Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

Feasibility Testing of a Dyadic Exercise Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers

A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

About this Non-Small Cell Lung Cancer clinical trials directory page